The price-to-book multiple near 1.24 suggests the market is valuing SABS at a modest premium to its liquidation-basis accounting equity, which is itself dominated by paid-in capital while retained earnings sit at -$152.3M — an equity base created by repeated raises, not compounding. Standard earnings and EBITDA multiples (EV/EBITDA, forward P/E) are unavailable, which is typical for a pre-commercial biotech but leaves investors without a growth-implied pricing benchmark; the P/B ratio becomes the de facto anchor and, in this case, may primarily reflect option value on pipeline assets rather than fundamental earnings capacity.

Because revenue was absent in seven of ten quarters and gross profit was negative across all periods, no margin decomposition can isolate operating leverage; the operating loss widening from -$10.0M in 2024Q4 to -$23.4M in 2026Q2 reflects an R&D and SG&A cost structure compounding independently of commercialization progress. The one adjustment that matters: 2025Q3's +$45.4M net income against a -$12.7M operating loss means headline net margin is unusable as an earning-power proxy across the trailing ten quarters, reinforcing that operating cash burn, not reported earnings, is the operative economic metric.

The 2025Q3 ROE print of +51.3% is an artifact of the one-time non-operating gain flowing through equity, not evidence of returns inflection — ROA of 42.6% in the same quarter coexisted with a negative ROIC of -12.1%, confirming the divergence between GAAT book equity and operating capital productivity. The modest sequential improvement in ROIC from -39.1% to roughly -8.3% appears driven primarily by denominator expansion from capital raises (total assets grew eightfold to $238.2M) rather than any narrowing of operating losses, so investors should treat the apparent trend improvement as balance-sheet-driven, not operations-driven.

Minimal fixed obligations preserve refinancing optionality and suggest covenant risk is negligible in the near term, which is one genuine strength relative to leveraged biotech peers. However, the negative coverage ratio should not be read as distress from debt service — it reflects the absence of positive operating income; the actual financial constraint is equity-funded burn, not interest expense, so traditional leverage screens will understate SABS's true financing risk profile.

The identical current and quick readings indicate inventory is not the liquidity constraint — the constraint is asset composition: with only $8.3M in cash against a -$26.7M quarterly FCF deficit and R&D spend accelerating past $13M per quarter, the spendable runway implied by the headline ratio appears materially overstated under a severe stress scenario. Combined with 2026Q2's step-up in capex to -$2.6M from negligible prior levels, the balance sheet's apparent fortress may depend on continued external capital access; investors should monitor cash balances and any subsequent raises as the true solvency indicator rather than the current ratio.